Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, ...

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic ...

Columnist Sam Kirton had to make some adjustments after his IPF diagnosis, but there are still plenty of ways to find joy, he says.

Patients with connective tissue disease-related interstitial lung disease show slower decline in lung function and longer ...

The 2014 publication of the ASCEND1 and INPULSIS2 trials and subsequent regulatory approvals of pirfenidone and nintedanib, respectively, represented a watershed moment in the treatment of patients ...

Background Smoking has been considered an important risk factor for idiopathic pulmonary fibrosis (IPF) incidence. However, there are no population-based large-scale studies demonstrating the effects ...

GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease ...

Introduction People with pulmonary fibrosis (PF) experience a high symptom burden, reduced quality of life and a shortened lifespan. Treatment options are limited and little is known about what ...

Chronic lung diseases, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), are major leading causes of death worldwide and are generally associated with poor ...

Citation: Sun J and Zeng Y (2025) Identification and analysis of diverse programmed cell death patterns in idiopathic pulmonary fibrosis using microarray-based transcriptome profiling and ...

In idiopathic pulmonary fibrosis (IPF), chronic epithelial injury triggered by persistent oxidative stress, inflammation, viral infections, aging and metabolic dysregulation drives the activation of ...